Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
NEW YORK, Feb. 11, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015 through September 28, 2015, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Esperion Therapeutics investors under the federal securities laws.
To join the Esperion Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-814.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that there was no clear path to approval for ETC-1002, the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”) and completion of a CVOT could be necessary prior to approval of ETC-1002. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-814.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
